Get the Stockscreener App
368.10
0.45%
1.66
After Hours:
368.50
0.40
+0.11%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $368.10, with a volume of 1.94M.
It is up +0.45% in the last 24 hours and up +5.30% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$366.44
Open:
$374.28
24h Volume:
1.94M
Relative Volume:
0.72
Market Cap:
$198.67B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
25.60
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+1.65%
1M Performance:
+5.30%
6M Performance:
+7.74%
1Y Performance:
+25.65%
1-Day Range:
$366.36
$375.25
1-Week Range:
$357.89
$375.25
52-Week Range:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
368.10 | 197.77B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,235.56 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.24 | 624.26B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.65 | 450.11B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.86 | 313.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
157.03 | 296.69B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Regeneron Ducks Amgen's Eylea Antitrust Counterclaims - Law360
How Safe Is Amgen's Dividend? - The Motley Fool
Amgen focuses on pipeline and strategy as investors watch earnings trajectory - AD HOC NEWS
Integrated Advisors Network LLC Raises Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Kiley Juergens Wealth Management LLC Takes $1.25 Million Position in Amgen Inc. $AMGN - MarketBeat
Hodges Capital Management Inc. Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc growth story and pipeline outlook - AD HOC NEWS
Amgen Inc. $AMGN Shares Sold by Burney Co. - MarketBeat
AMGN Maintained by Truist Securities -- Price Target Raised to $340 - GuruFocus
Amgen highlights its science-driven pipeline as investors weigh long-term growth - AD HOC NEWS
Amgen stock leans on its pipeline. Investors track a U.S. biotech giant. - AD HOC NEWS
Amgen highlights biotech strength as a large-cap innovator - AD HOC NEWS
Amgen (AMGN) Stock Dips While Market Gains: Key Facts - Yahoo Finance
2026 Best Places to Work in Kentucky rankings announced - pmg-ky1.com
The Dow Couldn't Keep Up With Chip Stocks on Monday - The Motley Fool
Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Amgen Slides as Tavneos Scrutiny and Pipeline Questions Weigh on Shares - Quiver Quantitative
AMGN Reiterated by Cantor Fitzgerald -- Price Target Maintained at $350 - GuruFocus
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $350 - Investing.com
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $350 By Investing.com - Investing.com Canada
Amgen Inc. $AMGN Shares Bought by Stephens Inc. AR - MarketBeat
Amgen Inc. (AMGN) Stock Analysis: Evaluating the 101% Return on Equity Amid a Diverse Portfolio - DirectorsTalk Interviews
Dividend Assets Capital LLC Sells 9,002 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Stock 12‑Month Price Target Raised to $355.04, Implies 5% Downside - TradingView
Ascentis Independent Advisors Acquires 8,192 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Could Be 45% Below Fair Value As Court Blocks Enbrel Price Cap - simplywall.st
AMGNAMGEN Inc Latest SEC Filings - Finviz
Amgen Stock: What Happened After a Judge Blocks Colorado’s Enbrel Price Cap? - TIKR.com
Vivid Wealth Management LLC Invests $2.46 Million in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by QRG Capital Management Inc. - MarketBeat
Amgen Inc. $AMGN Shares Sold by Simplify Asset Management Inc. - MarketBeat
Boston Trust Walden Corp Purchases 12,647 Shares of Amgen Inc. $AMGN - MarketBeat
Y Intercept Hong Kong Ltd Takes $11.40 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Peregrine Asset Advisers Inc. - MarketBeat
Strs Ohio Cuts Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Fights to Keep Avacopan on Market Amid Rising Concerns - Medscape
Amgen Inc. $AMGN Position Boosted by Elevation Point Wealth Partners LLC - MarketBeat
Amgen Inc. $AMGN Shares Sold by Fideuram Intesa Sanpaolo Private Banking S.P.A. - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 62,190 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Is Up, What You Need To Know - Yahoo Finance
A Look at Amgen Inc (AMGN) After 3.5% Gain -- GF Value $353.58 v - GuruFocus
With New Phase 3 Data, Roche Claims an Edge Over Amgen and BMS Lung Cancer Drugs - MedCity News
Amgen Inc Stock (AMGN) Moved Up by 3.01% on Jul 2: Key Drivers Unveiled - TradingKey
Does Tavneos Retraction And Possible Withdrawal Reshape The Bull Case For Amgen (AMGN)? - simplywall.st
Vertrix Wealth Management LLC Buys New Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stake Lessened by Fulton Bank N.A. - MarketBeat
Amgen Secures Court Halt to Colorado Board’s Price Cap on Enbrel - Bloomberg Law News
Amgen Wins Order Blocking Colorado's Enbrel Price Cap - Law360
Judge blocks Colorado’s first-of-its-kind price cap on Amgen’s Enbrel By Reuters - Investing.com
Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel - Reuters
Controversial drug at center of multibillion-dollar Amgen deal faces more questions after paper retracted - The Business Journals
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):